Warren Buffett's Successor, Greg Abel, Cashed Out on UnitedHealth. But Is the Stock a Steal at Its Current Valuation?

Berkshire Hathaway’s Greg Abel sold 5,039,564 UnitedHealth (UNH) shares earlier this year after Buffett added the stock in Q2, with the article framing this as part of a broader portfolio strategy rather than a clear loss of confidence. UNH is portrayed as on a recovery path—driven by cost/pricing plan adjustments and AI investments—while its valuation at ~23x forward earnings is “reasonably priced” versus Buffett’s entry after a valuation drop. The piece suggests UNH can continue benefiting from improving revenue growth prospects, though it isn’t viewed as a clear bargain at current multiples.

Analysis

The actionable signal is not the Berkshire trade; it is whether UnitedHealth has finally crossed from “fixing” to “compounding.” In managed care, that inflection is driven by medical-cost trend and pricing discipline, not revenue growth, so the key variable is whether recent plan pruning is enough to keep margins ahead of utilization. If yes, the market should reward UNH with multiple stability rather than a dramatic rerate; if not, 23x forward earnings leaves limited cushion.

Relative winners are the scaled operators with data, contracting leverage, and admin automation—UNH first, then peers like ELV—because they can reprice faster and absorb volatility better than smaller MA-exposed plans such as HUM. The second-order loser set includes providers and services businesses that rely on lenient utilization management; tighter benefit design and more aggressive prior auth can shift volume away from hospitals and outpatient names over the next 2-4 quarters. The AI/efficiency angle matters only if it shows up in SG&A and claims processing metrics, not in press-release language.

The near-term catalyst path is earnings and CMS/MA rate commentary over the next 1-3 months; that is where the thesis breaks or confirms. The contrarian miss is that Buffett/Abel flows are likely irrelevant versus fundamentals, and the market may be overpricing a “clean recovery” before we see sustained MLR improvement. The structural view over 6-18 months is constructive if UNH can keep growth moderate and margin expansion persistent, but any utilization re-acceleration, regulatory scrutiny on Optum integration, or a weaker MA rate environment would quickly cap upside.

Key Decisions for Investors

• Long UNH on a post-earnings or 5%+ pullback; hold 6-12 months. Upside is a slow grind higher if margins keep improving, but invalidation is a guide miss or MLR re-acceleration.
• Pair trade: long UNH / short HUM for 3-6 months. Thesis is that scale and pricing power matter more in a volatile utilization backdrop; risk is a broad MA rate tailwind lifting the whole group.
• If already long UNH, monetize implied-volatility spikes around earnings by selling covered calls or using call spreads instead of outright stock add-ons; the stock’s valuation reduces convexity.
• Watch ELV as a relative winner if UNH’s recovery proves real. A long ELV vs short HUM basket may offer cleaner managed-care exposure if UNH’s headline risk keeps its multiple capped.